0001104659-19-070217.txt : 20191205
0001104659-19-070217.hdr.sgml : 20191205
20191205163036
ACCESSION NUMBER: 0001104659-19-070217
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191204
FILED AS OF DATE: 20191205
DATE AS OF CHANGE: 20191205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ende Eric J
CENTRAL INDEX KEY: 0001494386
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37977
FILM NUMBER: 191270689
MAIL ADDRESS:
STREET 1: C/O MATINAS BIOPHARMA HOLDINGS, INC.
STREET 2: 1545 ROUTE 206 SOUTH, SUITE 302
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC
CENTRAL INDEX KEY: 0001012477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
STREET 2: BALLYCOOLIN
CITY: DUBLIN
STATE: L2
ZIP: 15
BUSINESS PHONE: 636-449-1830
MAIL ADDRESS:
STREET 1: 16640 CHESTERFIELD GROVE ROAD
STREET 2: SUITE 200
CITY: CHESTERFIELD
STATE: MO
ZIP: 63005
FORMER COMPANY:
FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA
DATE OF NAME CHANGE: 19960422
4
1
tm1924557-1_4.xml
OWNERSHIP DOCUMENT
X0306
4
2019-12-04
0
0001012477
AVADEL PHARMACEUTICALS PLC
AVDL
0001494386
Ende Eric J
C/O AVADEL PHARMACEUTICALS PLC
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
DUBLIN
L2
15
IRELAND
1
0
0
0
ADSs
2019-12-04
4
P
0
10000
5.97
A
47900
D
The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.94 to $5.99, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.
/s/ Phillandas T. Thompson as attorney in fact for Eric J. Ende
2019-12-05